Zobrazeno 1 - 10
of 860
pro vyhledávání: '"Mark D Minden"'
Autor:
Irakli Dzneladze, John F Woolley, Carla Rossell, Youqi Han, Ayesha Rashid, Michael Jain, Jüri Reimand, Mark D Minden, Leonardo Salmena
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0191510 (2018)
Our previous studies demonstrated that INPP4B, a member of the PI3K/Akt signaling pathway, is overexpressed in a subset of AML patients and is associated with lower response to chemotherapy and shorter survival. INPP4B expression analysis in AML reve
Externí odkaz:
https://doaj.org/article/0f0e67cd233c4de299e97dbd10a08166
Autor:
Ju Huang, Yuanfeng Liu, Bryan C Au, Dwayne L Barber, Andrea Arruda, Axel Schambach, Michael Rothe, Mark D Minden, Christopher J Paige, Jeffrey A Medin
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 3, Iss C (2016)
Interleukin-12 (IL-12) is a potent cytokine that may be harnessed to treat cancer. To date, nearly 100 IL-12-based clinical trials have been initiated worldwide. Yet systemic administration of IL-12 is toxic. Different strategies are being developed
Externí odkaz:
https://doaj.org/article/57606d1514384bb1a972cad69db16119
Autor:
Jae-Sook Ahn, Hyeoung-Joon Kim, Yeo-Kyeoung Kim, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Il-Kwon Lee, Nan Young Kim, Mark D Minden, Chul Won Jung, Jun-Ho Jang, Hee Je Kim, Joon Ho Moon, Sang Kyun Sohn, Jong-Ho Won, Sung-Hyun Kim, Namshin Kim, Kenichi Yoshida, Seishi Ogawa, Dennis Dong Hwan Kim
Publikováno v:
Haematologica, Vol 100, Iss 9 (2015)
Externí odkaz:
https://doaj.org/article/1fdf6398878241249c6e7a3b3013b85c
Autor:
Nicole M Anderson, Mojib Javadi, Elizabeth Berndl, Zorana Berberovic, Monica L Bailey, Kai Huang, Ann M Flenniken, Lucy R Osborne, S Lee Adamson, Janet Rossant, Christin Carter-Su, Chen Wang, Kelly M McNagny, Robert F Paulson, Mark D Minden, William L Stanford, Dwayne L Barber
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e75472 (2013)
Utilizing ENU mutagenesis, we identified a mutant mouse with elevated platelets. Genetic mapping localized the mutation to an interval on chromosome 19 that encodes the Jak2 tyrosine kinase. We identified a A3056T mutation resulting in a premature st
Externí odkaz:
https://doaj.org/article/0199f61192784ce99fbae49a0da0fce4
Autor:
Bozhena Jhas, Shrivani Sriskanthadevan, Marko Skrtic, Mahadeo A Sukhai, Veronique Voisin, Yulia Jitkova, Marcela Gronda, Rose Hurren, Rob C Laister, Gary D Bader, Mark D Minden, Aaron D Schimmer
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e58367 (2013)
Recently, we demonstrated that the anti-bacterial agent tigecycline preferentially induces death in leukemia cells through the inhibition of mitochondrial protein synthesis. Here, we sought to understand mechanisms of resistance to tigecycline by est
Externí odkaz:
https://doaj.org/article/a6b5eeea4bc343939e674921c570004d
Autor:
David B Rosen, Santosh Putta, Todd Covey, Ying-Wen Huang, Garry P Nolan, Alessandra Cesano, Mark D Minden, Wendy J Fantl
Publikováno v:
PLoS ONE, Vol 5, Iss 8, p e12405 (2010)
BACKGROUND:Single cell network profiling (SCNP) utilizing flow cytometry measures alterations in intracellular signaling responses. Here SCNP was used to characterize Acute Myeloid Leukemia (AML) disease subtypes based on survival, DNA damage respons
Externí odkaz:
https://doaj.org/article/50ef7e8905104bacbd9635d61ac5838f
Autor:
David B Rosen, Mark D Minden, Steven M Kornblau, Aileen Cohen, Urte Gayko, Santosh Putta, John Woronicz, Erik Evensen, Wendy J Fantl, Alessandra Cesano
Publikováno v:
PLoS ONE, Vol 5, Iss 10, p e13543 (2010)
BACKGROUND: Molecular characterization of the FMS-like tyrosine kinase 3 receptor (FLT3) in cytogenetically normal acute myeloid leukemia (AML) has recently been incorporated into clinical guidelines based on correlations between FLT3 internal tandem
Externí odkaz:
https://doaj.org/article/217b1e6b880441569c73c12d586c9493
Autor:
RuiQi Chen, Eshetu G. Atenafu, Jack Seki, Xing Liu, Steven Chan, Vikas Gupta, Dawn Maze, Andre C. Shuh, Mark D. Minden, Karen Yee, Aaron D. Schimmer, Hassan Sibai
Publikováno v:
British Journal of Haematology. 201:645-652
Autor:
Ana Vujovic, Laura de Rooij, Ava Keyvani Chahi, He Tian Chen, Brian A. Yee, Sampath K. Loganathan, Lina Liu, Derek C.H. Chan, Amanda Tajik, Emily Tsao, Steven Moreira, Pratik Joshi, Joshua Xu, Nicholas Wong, Zaldy Balde, Soheil Jahangiri, Sasan Zandi, Stefan Aigner, John E. Dick, Mark D. Minden, Daniel Schramek, Gene W. Yeo, Kristin J. Hope
Publikováno v:
Blood Cancer Discovery. 4:180-207
Acute myeloid leukemia (AML) is fueled by leukemic stem cells (LSC) whose determinants are challenging to discern from hematopoietic stem cells (HSC) or uncover by approaches focused on general cell properties. We have identified a set of RNA-binding
Autor:
Chang, Davidson Zhao, Mojgan Zarif, Qianghua Zhou, José-Mario Capo-Chichi, Andre Schuh, Mark D. Minden, Eshetu G. Atenafu, Rajat Kumar, Hong
Publikováno v:
Cancers; Volume 15; Issue 12; Pages: 3210
TP53 mutations are associated with extremely poor outcomes in acute myeloid leukemia (AML). The outcomes of patients with TP53-mutated (TP53MUT) AML after different frontline treatment modalities are not well established. Allogeneic hematopoietic cel